Trial Profile
Single-center, Retrospective, Matched Case-Cohort Study that Comparing Outcomes in Patients with NVAF taking Rivaroxaban with Concomitant without Concomitant Diltiazem
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 21 Aug 2018
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary) ; Diltiazem
- Indications Embolism and thrombosis
- Focus Therapeutic Use
- 21 Aug 2018 New trial record
- 13 Aug 2018 Results published in the Annals of Pharmacotherapy